Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative D... (stems andTransgenomic Pharmacogenomics a...)

HOME >> BIOLOGY >> TECHNOLOGY

Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics

Date:12/2/2008

stems, and Transgenomic Pharmacogenomics and Reference Laboratory Services. Transgenomic Pharmacogenomics and Laboratory Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: http://www.transgenomic.com.

About Power3 Medical

Power3 Medical Products, Inc. (OTCBB: PWRM, http://www.power3medical.com), is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as neurodegenerative disease (NuroPro(R)). Power3 expects to complete phase II and III clinical validation trials of its blood serum diagnostics for Alzheimer's disease, AD-NuroPro(R), in the third quarter of 2009 followed by completion of filing with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer's, and Parkinson's Diseases.

Transgenomic Cautionary Statements

'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
2. Transgenomic to Present at Rodman & Renshaw 10th Annual Healthcare Conference
3. Transgenomic, Inc. Reports Third Quarter 2008 Results
4. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2008 Earnings Release Conference Call Webcast
5. Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
6. Transgenomic Reports Second Quarter 2008 Results
7. Reminder: Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
8. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
9. Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
10. Webcast Alert: Transgenomic Inc. Announces First Quarter 2008 Earnings Release Conference Call Webcast
11. Transgenomic Opens Pharmacogenomics Laboratory in China

Post Your Comments:

Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative D...(stems andTransgenomic Pharmacogenomics a...)